Microalbuminuria: Risk factor and potential therapeutic target for stroke?

Journal of the Neurological Sciences

Volumn 271, Issue 1-2, 2008, Pages 21-28

  Ovbiagele, Bruce ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

Ischemic; Kidney Disease; Microalbuminuria; Risk factors; Stroke

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR; PRAVASTATIN; RAMIPRIL;

BLOOD PRESSURE REGULATION; BRAIN INFARCTION; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; DRUG TOLERABILITY; ENDOTHELIAL DYSFUNCTION; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; MICROALBUMINURIA; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SMOKING; STROKE; VASCULAR DISEASE;

ALBUMINURIA; ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; RISK FACTORS;

EID: 45849096499     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2008.04.007     Document Type: Review

References (51)

1. Brosius III F.C., Hostetter T.H., Kelepouris E., Mitsnefes M.M., Moe S.M., Moore M.A., et al. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney And Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation. Circulation 114 (2006) 1083-1087
2. Schiffrin E.L., Lipman M.L., and Mann J.F. Chronic kidney disease: effects on the cardiovascular system. Circulation 116 (2007) 85-97
3. Freedman B.I., and Dubose Jr. T.D. Chronic kidney disease: cause and consequence of cardiovascular disease. Arch Intern Med 167 (2007) 1113-1115
4. Park H.Y., Schumock G.T., Pickard A.S., and Akhras K. A structured review of the relationship between microalbuminuria and cardiovascular events in patients with diabetes mellitus and hypertension. Pharmacotherapy 23 (2003) 1611-1616
5. Donnelly R., Yeung J.M., and Manning G. Microalbuminuria: a common, independent cardiovascular risk factor, especially but not exclusively in type 2 diabetes. J Hypertens Suppl 21 (2003) S7-S12
6. Ochodnicky P., Henning R.H., van Dokkum R.P., and de Zeeuw D. Microalbuminuria and endothelial dysfunction: emerging targets for primary prevention of end-organ damage. J Cardiovasc Pharmacol 47 Suppl 2 (2006) S151-S162 discussion S72-A76
7. Pedrinelli R., Dell'Omo G., Di Bello V., Pontremoli R., and Mariani M. Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension. J Hum Hypertens 16 (2002) 79-89
8. Sarafidis P.A., and Bakris G.L. Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease. Nephrol Dial Transplant 21 (2006) 2366-2374
9. Levey A.S., Coresh J., Balk E., Kausz A.T., Levin A., Steffes M.W., et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139 (2003) 137-147
10. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. Jama 289 (2003) 2560-2572
11. Gerstein H.C., Mann J.F., Yi Q., Zinman B., Dinneen S.F., Hoogwerf B., et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. Jama 286 (2001) 421-426
12. Bennett P.H., Lee E.T., Lu M., Keen H., and Fuller J.H. Increased urinary albumin excretion and its associations in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 44 Suppl 2 (2001) S37-S45
13. Rudy A., Kowalska I., Straczkowski M., and Kinalska I. Homocysteine concentrations and vascular complications in patients with type 2 diabetes. Diabetes Metab 31 (2005) 112-117
14. Nakamura M., Onoda T., Itai K., Ohsawa M., Satou K., Sakai T., et al. Association between serum C-reactive protein levels and microalbuminuria: a population-based cross-sectional study in northern Iwate, Japan. Intern Med 43 (2004) 919-925
15. Pannacciulli N., Cantatore F.P., Minenna A., Bellacicco M., Giorgino R., and De Pergola G. Urinary albumin excretion is independently associated with C-reactive protein levels in overweight and obese nondiabetic premenopausal women. J Intern Med 250 (2001) 502-507
16. Yu Y., Suo L., Yu H., Wang C., and Tang H. Insulin resistance and endothelial dysfunction in type 2 diabetes patients with or without microalbuminuria. Diabetes Res Clin Pract 65 (2004) 95-104
17. Barzilay J.I., Peterson D., Cushman M., Heckbert S.R., Cao J.J., Blaum C., et al. The relationship of cardiovascular risk factors to microalbuminuria in older adults with or without diabetes mellitus or hypertension: the cardiovascular health study. Am J Kidney Dis 44 (2004) 25-34
18. Stehouwer C.D., Gall M.A., Twisk J.W., Knudsen E., Emeis J.J., and Parving H.H. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 51 (2002) 1157-1165
19. Gruden G., Cavallo-Perin P., Bazzan M., Stella S., Vuolo A., and Pagano G. PAI-1 and factor VII activity are higher in IDDM patients with microalbuminuria. Diabetes 43 (1994) 426-429
20. Deckert T., Feldt-Rasmussen B., Borch-Johnsen K., Jensen T., and Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 32 (1989) 219-226
21. Montalescot G., and Collet J.P. Preserving cardiac function in the hypertensive patient: why renal parameters hold the key. Eur Heart J 26 (2005) 2616-2622
22. Naidoo D.P. The link between microalbuminuria, endothelial dysfunction and cardiovascular disease in diabetes. Cardiovasc J S Afr 13 (2002) 194-199
23. Jensen J.S. Microalbuminaria and the risk of atherosclerosis. Clinical epidemiological and physiological investigations. Dan Med Bull 47 (2000) 63-78
24. Weir M.R. Reduction in microalbuminuria: a biomeasure of therapeutic success?. Hypertension 45 (2005) 181-182
25. Hillege H.L., Fidler V., Diercks G.F., van Gilst W.H., de Zeeuw D., van Veldhuisen D.J., et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106 (2002) 1777-1782
26. Roest M., Banga J.D., Janssen W.M., Grobbee D.E., Sixma J.J., de Jong P.E., et al. Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women. Circulation 103 (2001) 3057-3061
27. Yuyun M.F., Khaw K.T., Luben R., Welch A., Bingham S., Day N.E., et al. Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. Int J Epidemiol 33 (2004) 189-198
28. Klausen K.P., Scharling H., and Jensen J.S. Very low level of microalbuminuria is associated with increased risk of death in subjects with cardiovascular or cerebrovascular diseases. J Intern Med 260 (2006) 231-237
29. Wachtell K., Ibsen H., Olsen M.H., Borch-Johnsen K., Lindholm L.H., Mogensen C.E., et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 139 (2003) 901-906
30. Arnlov J., Evans J.C., Meigs J.B., Wang T.J., Fox C.S., Levy D., et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 112 (2005) 969-975
31. Wang T.J., Gona P., Larson M.G., Tofler G.H., Levy D., Newton-Cheh C., et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 355 (2006) 2631-2639
32. Blankenberg S., McQueen M.J., Smieja M., Pogue J., Balion C., Lonn E., et al. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 114 (2006) 201-208
33. Ravera M., Ratto E., Vettoretti S., Viazzi F., Leoncini G., Parodi D., et al. Microalbuminuria and subclinical cerebrovascular damage in essential hypertension. J Nephrol 15 (2002) 519-524
34. Rodondi N., Yerly P., Gabriel A., Riesen W.F., Burnier M., Paccaud F., et al. Microalbuminuria, but not cystatin C, is associated with carotid atherosclerosis in middle-aged adults. Nephrol Dial Transplant 22 (2007) 1107-1114
35. Furtner M., Kiechl S., Mair A., Seppi K., Weger S., Oberhollenzer F., et al. Urinary albumin excretion is independently associated with carotid and femoral artery atherosclerosis in the general population. Eur Heart J 26 (2005) 279-287
36. Woo H.M., Kang J.H., Kawada T., Yoo H., Sung M.K., and Yu R. Active spice-derived components can inhibit inflammatory responses of adipose tissue in obesity by suppressing inflammatory actions of macrophages and release of monocyte chemoattractant protein-1 from adipocytes. Life Sci 80 (2007) 926-931
37. Kagan A., Popper J.S., Rhoads G.G., and Yano K. Dietary and other risk factors for stroke in Hawaiian Japanese men. Stroke 16 (1985) 390-396
38. Madison J.R., Spies C., Schatz I.J., Masaki K., Chen R., Yano K., et al. Proteinuria and risk for stroke and coronary heart disease during 27 years of follow-up: the Honolulu Heart Program. Arch Intern Med 166 (2006) 884-889
39. Yuyun M.F., Khaw K.T., Luben R., Welch A., Bingham S., Day N.E., et al. Microalbuminuria and stroke in a British population: the European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. J Intern Med 255 (2004) 247-256
40. Ovbiagele B. Impairment in glomerular barrier or filtration rate and occurrence of stroke. Arch Neurol in press.
41. Hillege H.L., Janssen W.M., Bak A.A., Diercks G.F., Grobbee D.E., Crijns H.J., et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 249 (2001) 519-526
42. Slowik A., Turaj W., Iskra T., Strojny J., and Szczudlik A. Microalbuminuria in nondiabetic patients with acute ischemic stroke: prevalence, clinical correlates, and prognostic significance. Cerebrovasc Dis 14 (2002) 15-21
43. Terao Y., Takada M., Tanabe T., Ando Y., Fukusaki M., and Sumikawa K. Microalbuminuria is a prognostic predictor in aneurysmal subarachnoid hemorrhage. Intensive Care Med 33 (2007) 1000-1006
44. Hitman G.A., Colhoun H., Newman C., Szarek M., Betteridge D.J., Durrington P.N., et al. Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabet Med 24 (2007) 1313-1321
45. Gillett M., Davis W.A., Jackson D., Bruce D.G., and Davis T.M. Prospective evaluation of carotid bruit as a predictor of first stroke in type 2 diabetes: the Fremantle Diabetes Study. Stroke 34 (2003) 2145-2151
46. *. J Hypertens 24 (2006) 541-548
47. Davis T.M., Millns H., Stratton I.M., Holman R.R., and Turner R.C. Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29. Arch Intern Med 159 (1999) 1097-1103
48. Beamer N.B., Coull B.M., Clark W.M., and Wynn M. Microalbuminuria in ischemic stroke. Arch Neurol 56 (1999) 699-702
49. Cao J.J., Barzilay J.I., Peterson D., Manolio T.A., Psaty B.M., Kuller L., et al. The association of microalbuminuria with clinical cardiovascular disease and subclinical atherosclerosis in the elderly: the Cardiovascular Health Study. Atherosclerosis 187 (2006) 372-377
50. de Zeeuw D., Remuzzi G., Parving H.H., Keane W.F., Zhang Z., Shahinfar S., et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110 8 (2004) 921-927
51. Asselbergs F.W., Diercks G.F., Hillege H.L., van Boven A.J., Janssen W.M., Voors A.A., et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 110 (2004) 2809-2816